Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (50.0%)
N/A2 (50.0%)

Trials by Status

unknown125%
not_yet_recruiting125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable

Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

NCT07379177
unknownnot_applicable

Effect of Nano-curcumin Supplementation in Acute Pancreatitis

NCT04989166
completedphase_2

The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients

NCT03140657
completedphase_2

The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients

NCT03150966

Clinical Trials (4)

Showing 4 of 4 trials
NCT07379177Not Applicable

Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

Not Yet Recruiting
NCT04989166Not Applicable

Effect of Nano-curcumin Supplementation in Acute Pancreatitis

Unknown
NCT03140657Phase 2

The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients

Completed
NCT03150966Phase 2

The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
4